{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.1","upperLimit":"94.1","value":"6.6"},{"groupId":"OG001","lowerLimit":"5.9","upperLimit":"25.9","value":"6.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"title":"First Line Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.1","upperLimit":"37.0","value":"12.9"},{"groupId":"OG001","lowerLimit":"6.4","upperLimit":"18.9","value":"9.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Second Line Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"TTR was defined as the time from the date of first dose to first radiographic evidence of response (CR or PR) per RECIST v1.1 as assessed by response reported by investigator on eCRF. CR: disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR: \\>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. In this outcome measure, TTR for first line (no prior treatment) and second line (participant received a prior treatment defined as advanced/metastatic or locoregional disease or maintenance or if neoadjuvant/adjuvant with a disease recurrence occurred during or within 6 months of the last dose of therapy) were reported.","dispersionType":"Full Range","groups":[{"description":"Participants received encorafenib 300 milligrams (mg) once daily (QD) orally (received after Cycle 1 Day 3) and cetuximab 500 mg per square meters (mg/m\\^2) intravenous (IV) infusion for 120 minutes once every 2 weeks (Q2W) along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and irinotecan 180 mg/m\\^2 as IV infusion for 90 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG000","title":"SLI: Cohort 1 [EC + FOLFIRI]"},{"description":"Participants received encorafenib 300 mg QD orally and cetuximab 500 mg/m\\^2 IV infusion for 120 minutes Q2W along with fluorouracil 400 mg/m\\^2 IV bolus then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours Q2W; leucovorin 400 mg/m\\^2 IV infusion for 120 minutes Q2W and oxaliplatin 85 mg/m\\^2 IV infusion for 120 minutes Q2W. Participants received treatment in 28-day cycles.","id":"OG001","title":"SLI: Cohort 2 [EC + mFOLFOX6]"}],"paramType":"MEDIAN","populationDescription":"The FAS for SLI included all participants who were randomized in the SLI portion of the study. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure with a confirmed objective response as assessed by investigator and \"Number Analyzed\" signifies participants evaluable for specified rows. All participants under \"Overall Number of Participants Analyzed\" contributed data to the table but may not have data evaluable for each row.","reportingStatus":"POSTED","timeFrame":"From date of first dose to first radiographic evidence of response (CR or PR) (maximum up to 33.9 months [147.3 weeks])","title":"SLI: Time to Response (TTR) as Assessed by Investigator According to Line of Therapy - FAS","type":"SECONDARY","unitOfMeasure":"Weeks"}